Galectin Therapeutics Inc (GALT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $307.59M
Last updated: Nov 17, 2026 at 11:02 AM ET
Galectin Therapeutics Inc (GALT) Earnings: Report Dates and Results
Galectin Therapeutics (GALT) is expected to report earnings on Mar 29, 2027. In the quarter ended Jun 30, 2026, Galectin Therapeutics reported EPS of -$0.14, below the -$0.09 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
GALT has an expected report date of Mar 29, 2027.
Earnings History
Of the 40 quarters below that had an estimate, GALT beat 23, missed 13 and matched 4. The widest gap in the table came in the quarter ended Dec 31, 2019, when EPS landed 100.00% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$0.14 | -$0.09 | -$0.09 - -$0.09 | -55.56% | Miss | N/A | 1 | 0 up, 0 down | Aug 14, 2026 |
| Mar 31, 2026 | -$0.08 | -$0.06 | -$0.06 - -$0.06 | -33.33% | Miss | N/A | 1 | 0 up, 0 down | May 15, 2026 |
| Dec 31, 2025 | -$0.08 | -$0.10 | -$0.10 - -$0.10 | +20.00% | Beat | N/A | 1 | 1 up, 0 down | Mar 31, 2026 |
| Sep 30, 2025 | -$0.13 | -$0.11 | -$0.11 - -$0.11 | -18.18% | Miss | N/A | 1 | 1 up, 0 down | Nov 14, 2025 |
| Jun 30, 2025 | -$0.12 | -$0.16 | N/A | +25.00% | Beat | N/A | N/A | 0 up, 0 down | Aug 14, 2025 |
| Mar 31, 2025 | -$0.15 | -$0.11 | N/A | -36.36% | Miss | N/A | N/A | 0 up, 0 down | May 15, 2025 |
| Dec 31, 2024 | -$0.19 | -$0.16 | N/A | -18.75% | Miss | N/A | N/A | 0 up, 0 down | Mar 31, 2025 |
| Sep 30, 2024 | -$0.18 | -$0.20 | -$0.20 - -$0.20 | +10.00% | Beat | N/A | 1 | 0 up, 0 down | Nov 14, 2024 |
| Jun 30, 2024 | -$0.20 | -$0.16 | N/A | -25.00% | Miss | N/A | N/A | 0 up, 0 down | Aug 13, 2024 |
| Mar 31, 2024 | -$0.19 | -$0.16 | -$0.16 - -$0.16 | -18.75% | Miss | N/A | 1 | 0 up, 0 down | May 15, 2024 |
| Dec 31, 2023 | -$0.16 | -$0.16 | N/A | 0.00% | In line | N/A | N/A | 0 up, 0 down | Mar 29, 2024 |
| Sep 30, 2023 | -$0.24 | -$0.16 | -$0.16 - -$0.16 | -50.00% | Miss | N/A | 1 | 0 up, 0 down | Nov 13, 2023 |
| Jun 30, 2023 | -$0.15 | -$0.21 | N/A | +28.57% | Beat | N/A | N/A | 0 up, 0 down | Aug 14, 2023 |
| Mar 31, 2023 | -$0.19 | -$0.21 | -$0.21 - -$0.21 | +9.52% | Beat | N/A | 1 | 0 up, 0 down | May 15, 2023 |
| Dec 31, 2022 | -$0.18 | -$0.17 | -$0.17 - -$0.17 | -5.88% | Miss | N/A | 1 | 0 up, 0 down | Mar 30, 2023 |
| Sep 30, 2022 | -$0.14 | -$0.20 | -$0.20 - -$0.20 | +30.00% | Beat | N/A | 1 | 0 up, 0 down | Nov 14, 2022 |
| Jun 30, 2022 | -$0.16 | -$0.19 | N/A | +15.79% | Beat | N/A | N/A | 0 up, 0 down | Aug 15, 2022 |
| Mar 31, 2022 | -$0.17 | -$0.14 | -$0.14 - -$0.14 | -21.43% | Miss | N/A | 1 | 0 up, 0 down | May 16, 2022 |
| Dec 31, 2021 | -$0.12 | -$0.19 | -$0.19 - -$0.19 | +36.84% | Beat | N/A | 1 | N/A | Mar 31, 2022 |
| Sep 30, 2021 | -$0.14 | -$0.18 | -$0.18 - -$0.18 | +22.22% | Beat | N/A | 1 | N/A | Nov 15, 2021 |
| Jun 30, 2021 | -$0.15 | -$0.18 | -$0.18 - -$0.18 | +16.67% | Beat | N/A | 1 | N/A | Aug 16, 2021 |
| Mar 31, 2021 | -$0.11 | -$0.17 | -$0.17 - -$0.17 | +35.29% | Beat | N/A | 1 | N/A | May 17, 2021 |
| Dec 31, 2020 | -$0.13 | -$0.16 | -$0.16 - -$0.16 | +18.75% | Beat | N/A | 1 | N/A | Mar 31, 2021 |
| Sep 30, 2020 | -$0.10 | -$0.14 | -$0.14 - -$0.14 | +28.57% | Beat | N/A | 1 | N/A | Nov 9, 2020 |
| Jun 30, 2020 | -$0.11 | -$0.07 | -$0.12 - -$0.07 | -57.14% | Miss | N/A | 2 | N/A | Aug 10, 2020 |
| Mar 31, 2020 | -$0.06 | -$0.09 | -$0.11 - -$0.07 | +33.33% | Beat | N/A | 2 | N/A | May 11, 2020 |
| Dec 31, 2019 | -$0.12 | -$0.06 | -$0.06 - -$0.06 | -100.00% | Miss | N/A | 2 | N/A | Mar 16, 2020 |
| Sep 30, 2019 | -$0.05 | -$0.10 | -$0.10 - -$0.07 | +50.00% | Beat | N/A | 2 | N/A | Nov 12, 2019 |
| Jun 30, 2019 | -$0.06 | -$0.12 | -$0.18 - -$0.06 | +50.00% | Beat | N/A | 2 | N/A | Aug 9, 2019 |
| Mar 31, 2019 | -$0.20 | -$0.14 | -$0.20 - -$0.08 | -42.86% | Miss | N/A | 2 | N/A | May 10, 2019 |
| Dec 31, 2018 | -$0.08 | -$0.08 | -$0.08 - -$0.08 | 0.00% | In line | N/A | 2 | N/A | Mar 6, 2019 |
| Sep 30, 2018 | -$0.07 | -$0.09 | -$0.09 - -$0.09 | +22.22% | Beat | N/A | 1 | N/A | Nov 13, 2018 |
| Jun 30, 2018 | -$0.11 | -$0.11 | -$0.12 - -$0.11 | 0.00% | In line | N/A | 2 | N/A | Aug 14, 2018 |
| Mar 31, 2018 | -$0.12 | -$0.13 | -$0.17 - -$0.09 | +7.69% | Beat | N/A | 2 | N/A | May 11, 2018 |
| Dec 31, 2017 | -$0.07 | -$0.11 | -$0.12 - -$0.11 | +36.36% | Beat | N/A | 3 | N/A | Mar 29, 2018 |
| Sep 30, 2017 | -$0.13 | -$0.15 | N/A | +13.33% | Beat | N/A | N/A | N/A | Nov 7, 2017 |
| Jun 30, 2017 | -$0.14 | -$0.15 | N/A | +6.67% | Beat | N/A | N/A | N/A | Aug 14, 2017 |
| Mar 31, 2017 | -$0.15 | -$0.15 | N/A | 0.00% | In line | N/A | N/A | N/A | May 15, 2017 |
| Dec 31, 2016 | -$0.12 | -$0.17 | N/A | +29.41% | Beat | N/A | N/A | N/A | Mar 28, 2017 |
| Sep 30, 2016 | -$0.19 | -$0.22 | N/A | +13.64% | Beat | N/A | N/A | N/A | Nov 8, 2016 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.48, after -$0.76 the year before. It was -$0.75 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.48 | N/A |
| Dec 31, 2024 | -$0.76 | N/A |
| Dec 31, 2023 | -$0.74 | N/A |
| Dec 31, 2022 | -$0.65 | N/A |
| Dec 31, 2021 | -$0.52 | N/A |
| Dec 31, 2020 | -$0.40 | N/A |
| Dec 31, 2019 | -$0.43 | N/A |
| Dec 31, 2018 | -$0.38 | N/A |
| Dec 31, 2017 | -$0.49 | N/A |
| Dec 31, 2016 | -$0.75 | N/A |
Frequently Asked Questions About GALT
When is Galectin Therapeutics's next earnings date?
Galectin Therapeutics's next earnings report is expected for Mar 29, 2027.
Did GALT beat earnings estimates last quarter?
No. Galectin Therapeutics reported EPS of -$0.14 for the quarter ended Jun 30, 2026, below the -$0.09 estimate by 55.56%.
What EPS do analysts expect from GALT next quarter?
The consensus EPS estimate for Galectin Therapeutics for the quarter ending Dec 31, 2026 is -$0.05 from 3 analysts, with estimates from -$0.05 to -$0.05.
How often does GALT beat earnings estimates?
Galectin Therapeutics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -13.40%.
GALT pages: Overview, Earnings, Forecast, Financials, Competitors